Clinical Trial Results:
            A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediatric vaccination at 2, 4, 6 and 12-18 months of age, and to explore the ability of this schedule to accelerate the acquisition of pertussis antibodies.
    
|     Summary | |
|     EudraCT number | 2009-012460-14 | 
|     Trial protocol | NL GB BE | 
|     Global completion date | 
                                    26 Aug 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    30 Jan 2019
                             | 
|     First version publication date | 
                                    30 Jan 2019
                             | 
|     Other versions | |
|     Summary report(s) | Cancelled before Active Statement | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
